logo-loader
viewCircassia Group PLC

Circassia Pharma shares jump as CIP Merchant Capital buys 3.4% stake for £2.8mln

The investment firm said it has acquired 12.8mln shares in the specialty biopharmaceutical company focused on allergy and respiratory diseases

Circassia Pharmaceuticals PLC - Circassia’s shares acquired by CIP Merchant Capital for £2.8mln
CIP pointed out that its board "believes Circassia has a clear route to profitability"

Circassia Pharmaceuticals PLC (LON:CIR) shares jumped higher on Friday afternoon after news private equity firm CIP Merchant Capital Ltd (LON:CIP) has bought over a 3% stake in the company.

In a statement, the investment firm said it has acquired 12.8mln shares in Circassia, a specialty biopharmaceutical company focused on allergy and respiratory diseases, for £2.8mln. That represents 3.4% of Circassia's issued share capital, Circassia now constitutes the CIP's seventh portfolio company.

READ: Circassia to hit sales target as cash position improves

CIP pointed out that its board "believes Circassia has a clear route to profitability, having recently announced that the revenues for the 2019 year are expected to fall in the mid-range of its previously issued guidance of £60-£65 million." 

It also noted out In April 2019, Circassia announced the US Food and Drug Administration approval of Duaklir, a drug for maintenance treatment of chronic obstructive pulmonary disease, which was later launched in October 2019.

The investment group added: "Circassia has also recently made what the Board believes to be positive changes to its leadership team, hiring executives with a proven track record."

On Thursday, Circassia announced the appointment of Michael Roller, previously finance director at Corin Group and Bioquell, where he worked with Circassia’s executive chairman Ian Johnson, who was appointed last month.

Circassia shares rose 10.8% to 23.60p.

Quick facts: Circassia Group PLC

Price: 26.1 GBX

LSE:CIR
Market: LSE
Market Cap: £98.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read